Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Maze Therapeutics, Inc.NASDAQ: MAZE
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin at -132.8%
Operating margin was -132.8% in Q1 FY2026. On a trailing-twelve-month basis it was -670.3%, down 700.2 pp year over year.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2024
- 34.4%
- Year-over-year change
- —
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | — | — |
| FY2024 | 2024-12-31 | 34.4% | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | — | — |
Operating Margin vs competitors
How MAZE compares with its peers on the latest reported figures
- MAZE's LTM Mar 2026 operating margin of -670.3% is the 5th highest of the 7 companies compared; the peer median is -48.4%.
- Its year-over-year change of -700.2 pp is the 6th highest of 7, against a peer median of +1.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 11.5% | -29.2 pp | +113.5 pp | |
| LTM Mar 2026 | -8.7% | +2.2 pp | +112.2 pp | |
| LTM Sep 2026 | -20.5% | +0.4 pp | +279.4 pp | |
SEPNSepterna, Inc. | LTM Sep 2026 | -76.2% | +273.0 pp | — |
| LTM Mar 2026 | -670.3% | -700.2 pp | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -985.9% | +4653.4 pp | — |
| FY2025 | -2921.0% | -1860.3 pp | -2452.0 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding MAZE) | -48.4% | +1.3 pp | +112.8 pp | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 167.5M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 2.4M |
| Gross Profit | 0 | 0 | 167.5M | (2.4M) |
| Gross Margin | — | — | 100.0% | — |
| Research & Development | 88.19M | 73.95M | 83.5M | 108.45M |
| Selling, General & Admin | 22.83M | 24.61M | 26.42M | 34.45M |
| Operating Expenses | 111.03M | 98.55M | 109.91M | 140.5M |
| Depreciation & Amortization | 3.82M | 4.09M | 3.3M | 2.4M |
| EBITDA | (111.12M) | (96.33M) | 56.7M | (128.72M) |
| EBITDA Margin | — | — | 33.9% | — |
| Operating Income | (111.03M) | (98.55M) | 57.59M | (142.9M) |
| Operating Margin | — | — | 34.4% | — |
| Interest Income | 2.03M | 1.97M | 4.65M | 11.78M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (3.91M) | (1.86M) | (4.18M) | 11.78M |
| Income Before Tax | (114.94M) | (100.42M) | 53.4M | (131.12M) |
| Pre-Tax Margin | — | — | 31.9% | — |
| Income Tax Expense | 0 | 0 | 1.17M | 0 |
| Net Income | (114.94M) | (100.42M) | 52.23M | (131.12M) |
| Net Margin | — | — | 31.2% | — |
| EPS (Basic) | (2.63) | (2.29) | 0.08 | (3.05) |
| EPS (Diluted) | (2.63) | (2.29) | 0.08 | (3.05) |
| Weighted Avg Shares | 43.78M | 43.78M | 43.8M | 42.98M |
| Weighted Avg Shares (Diluted) | 43.78M | 43.78M | 43.8M | 42.98M |
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.